Candriam SCA
SNDX icon

Candriam SCA’s Syndax Pharmaceuticals SNDX Stock Holding History

Candriam SCA’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$31.5M Sell
1,670,510
-25,530
-2% -$516K 0.14% 143
2026
Q2 		$37M Buy
1,696,040
+770,708
+83% +$16M 0.17% 126
2026
Q1 		$21.6M Hold
925,332
– – 0.11% 182
2025
Q4 		$19.4M Hold
925,332
– – 0.1% 191
2025
Q3 		$14.2M Buy
925,332
+250,247
+37% +$3.28M 0.07% 221
2025
Q2 		$6.32M Buy
675,085
+224,650
+50% +$2.47M 0.04% 315
2025
Q1 		$5.53M Sell
450,435
-96,730
-18% -$1.36M 0.03% 312
2024
Q4 		$7.23M Sell
547,165
-451,454
-45% -$7.73M 0.04% 304
2024
Q3 		$19.2M Buy
998,619
+28,513
+3% +$589K 0.11% 184
2024
Q2 		$19.9M Sell
970,106
-74,926
-7% -$1.57M 0.12% 169
2024
Q1 		$24.9M Buy
1,045,032
+24,000
+2% +$535K 0.16% 139
2023
Q4 		$22.1M Buy
1,021,032
+781,022
+325% +$12M 0.15% 151
2023
Q3 		$3.48M Hold
240,010
– – 0.02% 357
2023
Q2 		$5.02M Sell
240,010
-14,864
-6% -$309K 0.04% 331
2023
Q1 		$4.95M Buy
+254,874
New +$6.34M 0.03% 366
2021
Q2 		– Sell
-25,671
Closed -$548K – 936
2021
Q1 		$548K Hold
25,671
– – ﹤0.01% 704
2020
Q4 		$571K Sell
25,671
-332,701
-93% -$6.9M ﹤0.01% 717
2020
Q3 		$5.29M Buy
358,372
+10,914
+3% +$166K 0.05% 347
2020
Q2 		$5.15M Buy
+347,458
New +$5.29M 0.05% 325
2018
Q1 		– Sell
-70,000
Closed -$613K – 786
2017
Q4 		$613K Buy
+70,000
New +$693K 0.01% 647

Other funds holding SNDX

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return
Torray Investment Partners
Torray Investment Partners Bethesda, Maryland $758M AUM 24.76% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Pavaki Capital Management
Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Harbour Capital Advisors
Harbour Capital Advisors Tysons Corner, Virginia $548M AUM 37.76% 1-Year Est. Return

Candriam SCA's SNDX Position: Q3 2026 in Review

Candriam SCA reduced its Syndax Pharmaceuticals (SNDX) stake by 1.5% in Q3 2026, selling an estimated $516K and leaving 1,670,510 shares worth $31.5M. The position accounts for 0.14% of the portfolio, ranked #143.

Candriam SCA first reported a position in SNDX in Q4 2017 and has held it in 20 quarters since. The position peaked at $37M in Q2 2026. 51 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.

  • Candriam SCA held 1,670,510 shares of Syndax Pharmaceuticals worth $31.5M as of Q3 2026.
  • Candriam SCA sold 25,530 Syndax Pharmaceuticals shares in Q3 2026, an estimated $516K.
  • Syndax Pharmaceuticals made up 0.14% of Candriam SCA's portfolio in Q3 2026, its #143 holding.
  • Candriam SCA first reported a position in Syndax Pharmaceuticals in Q4 2017 and has held it in 20 quarters since.
  • Candriam SCA's Syndax Pharmaceuticals position peaked at $37M in Q2 2026.
  • 51 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.